Frequently asked questions

What is Cellectis’ role in the fight against cancer?

Cellectis' product candidates, based on allogeneic gene-edited T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancers. A key to this effort is a type of white blood cell known as the T-cell, which plays an important role in identifying and killing cancer cells. Unfortunately, cancer cells often develop mechanisms to evade the immune system. CARs, which are engineered receptors that can be expressed on the surface of the T-cell, provide the T-cell with a specific targeting mechanism, thereby enhancing its ability to seek, identify, interact with and destroy tumor cells bearing a selected antigen. Cellectis is designing next-generation immunotherapies that are based on gene-edited CAR T-cells. Our gene-editing technologies allow us to create allogeneic CAR T-cells, meaning they are derived from healthy donors rather than the patients themselves.

What therapeutic innovations is Cellectis currently developing?

Cellectis is developing innovative allogeneic immunotherapies using its gene editing expertise to treat certain cancers. Cellectis product candidates are in development stage and are not authorized for commercialization.

How far along are Cellectis’ cancer treatment solutions?

Cellectis' pipeline, which keeps track of our product candidates' development, is constantly evolving. This pipeline is available under the Products section, Products candidates subsection.

What stock exchange is Cellectis listed on?

Cellectis’ shares are listed on the Alternext market of Euronext in Paris under ISIN code FR0010425595 and the ticker symbol ALCLS. In the U.S., they are also listed on the Nasdaq Global Market under the ticker symbol CLLS.

What day was Cellectis first listed?

Trading began on February 7, 2007 on the Alternext market of Euronext in Paris, and on March 25th, 2015 on the Nasdaq Global Market in the U.S.

What is Cellectis’ position regarding the defense of its patents?

At Cellectis, we attach great importance to the protection of our technology, intellectual property rights and our patents, and we take an active approach to defending our intellectual property.

How many Cellectis shares are in circulation, and how many voting rights?

As of August 31, 2017, the number of shares constituting Cellectis’ capital is 35,415,473. As of the same date, the number of double voting rights is 5,289,529.

How can I purchase Cellectis shares?

To purchase Cellectis shares, you must have an account with a financial intermediary (bank, brokerage firm, online broker, etc.) and place your order through them.

What documents are published to help shareholders stay informed of the Group’s affairs and performance?

Every year, Cellectis publishes a business report on the preceding year, which can be found on our website; this document can also be sent to you on request. In addition, Cellectis files a 20-F form with the SEC, available on our website. Our press releases can also be found on our website under the Press section.

How can I take part in Shareholders’ General Meetings?

If you are holder of Cellectis shares, you can participate in Shareholders’ General Meetings. To attend, send a proxy, or vote by mail, you must have your shares booked as registered shares with the Company or bearer shares with an authorized intermediary, no later than three business days before the date of the Meeting. For more information, go to Investors section, General Meetings subsection. If you are holder of ADS, please contact our depositary of ADS.

How do I vote at Shareholders’ General Meetings?

Each shareholder has as many votes as are conferred by the number of Cellectis shares he/she owns or represents. Rather than personally attending a Meeting, you may vest another shareholder or your spouse with power of attorney to represent you by proxy. For more information, go to Investors section, General Meetings subsection.

Does Cellectis pay dividends to its shareholders?

For the time being, we do not pay dividends to our shareholders because, like the vast majority of biotechnology companies, Cellectis does not yet generate profits.

What is the liquidity provider’s agreement?

A liquidity provider’s agreement is a signed contract between a securities issuer and an investment services provider whose role it is to buy or sell shares of the issuing company if the market for those shares becomes unbalanced or illiquid. The investment services provider thus contributes additional liquidity to the company’s shares and enhances the flow of transactions.

Why can’t we have more financial information on main agreements?

For the sake of transparency, our press releases include the financial terms of our main agreements insofar as we are authorized.

Where can I find a glossary of terms specific to what Cellectis does?

A glossary of terms specific to Cellectis’ business activities is available on our website, under Glossary (in the footer of each page).